



# Corporate Presentation

**November 2023**

Advancing medicines.  
Solving problems.  
Improving lives.

# Disclaimer

This presentation and the accompanying oral commentary has been prepared by Aquestive Therapeutics, Inc. (the “Company”, “our” or “us”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film for the emergency treatment of severe allergic reactions, including anaphylaxis, through clinical development and approval by the U.S. Food and Drug Administration (FDA), including the filing of our pivotal pharmacokinetic (PK) clinical trial and other supporting clinical studies for Anaphylm; regarding the advancement and related timing through clinical development and approval by the FDA of the Company’s New Drug Application (NDA) for our product candidate Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy between two and five years of age; regarding the approval for U.S. market access of Libervant for these epilepsy patients aged 12 years and older, and overcoming the orphan drug market exclusivity of an FDA approved nasal spray product of another company extending to January 2027 for this age group of the patient population; regarding the potential benefits our products and product candidates could bring to patients; regarding the potential for licensing to third parties our product candidate Anaphylm outside of the U.S. and Libervant in the U.S. and around the world; regarding the ability to bring our product candidates, including Anaphylm and Libervant, to market and achieve market acceptance of those products; regarding the rate and degree of market acceptance and demand for our licensed products; regarding the potential and related timing for expanding the Company’s manufacturing capabilities and supporting the growth of demand for existing and potential future licensed products in the U.S. and other countries and growing revenue from such activities; regarding the 2023 financial outlook of the Company and its growth and future financial and operating results and financial position; and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of global business and macroeconomic conditions, including as a result of inflation, rising interest rates, instability in the global banking system, and geopolitical conflicts, including the wars in Ukraine and Israel, and the impact of the COVID-19 global pandemic on the Company’s business including with respect to its clinical trials including site initiation, enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approval of Anaphylm and Libervant, pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; and ongoing availability of an appropriate labor force and skilled professionals.

These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials for Anaphylm, Libervant and our other product candidates; risk of the Company’s ability to generate sufficient data in the clinical trials for FDA approval of Anaphylm and Libervant for epilepsy patients between 2 and 5 years of age; risk of the Company’s ability to address the FDA’s comments on the Company’s pivotal PK study protocol and other concerns identified in the FDA End-of-Phase 2 meeting for Anaphylm; risk that the FDA may require additional clinical studies for approval of Anaphylm and Libervant for patients epilepsy between 2 and 5 years of age; risk of delays in or the failure to receive FDA approval of Anaphylm, Libervant and our other product candidates; risks that the FDA will not approve Libervant for U.S. market access for any age group of patients by overcoming the seven year orphan drug market exclusivity of an FDA approved nasal spray product in effect until January 2027, and there can be no assurance that the Company will be successful in obtaining any of the foregoing FDA approvals for Anaphylm and Libervant, including for U.S. market access for Libervant for any age group of patients; risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company’s receipt of FDA approval of the Libervant NDA for these epilepsy patients between 2 and 5 years of age; risk relating to the unpredictability of the FDA’s decisions regarding orphan drug exclusivity; risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of this epilepsy patient population; risk in obtaining market access for Libervant for other reasons; risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development activities; risk of the success of any competing products; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks, and regulatory limitations); risk of the rate and degree of market acceptance of our product candidates, including Anaphylm and Libervant, and our licensed products in the U.S. and abroad; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing and revenues from operations, to satisfy all of the Company’s short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund future clinical development activities for Anaphylm, Libervant and our other product candidates; risk that our manufacturing capabilities will be sufficient to support demand for existing and potential future licensed products in the U.S. and other countries; risk of achieving growth in our base business; risk of our ability to enter into other commercial transactions with third parties that will support growth of our business and execution of key initiatives; risk of the success of any competing products; risk of eroding market share for Suboxone® and risk as a sunset product, which accounts for the substantial part of our current operating revenue; risk of the size and growth of our product markets; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company’s products; risk of unexpected patent developments; uncertainties related to general economic, political (including acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items; and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in the Company’s 2022 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this presentation whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. The trade name for AQST-109 “Anaphylm” has been conditionally approved by the FDA. Final approval of the Anaphylm™ proprietary name is conditioned on FDA approval of the product candidate, AQST-109. All other registered trademarks referenced herein are the property of their respective owners.

## Our Mission

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies



# We Have a Strong Vision for Building the Company

**In the next five years, we aim to:**

- Grow the existing and ex-U.S. collaboration revenue
- Secure FDA approval for Anaphylm™ in the U.S.
- Launch Libervant™ in the U.S. in or prior to 2027<sup>1</sup>
- Advance product candidates utilizing Adrenaverse™ platform (epinephrine prodrug platform)

1. Estimate is based on an orphan drug market exclusivity block until January of 2027 by an FDA approved nasal spray product.

# Aquestive Is a Growth Story With Multiple Assets

Revenue-Generating Base of Existing Collaborations	Potential for Commercialization Events in or Prior to 2027	Pipeline Renewal
<ul style="list-style-type: none"><li>• 5 FDA-approved products</li><li>• 8 Collaborations</li><li>• 10+ years of product sales on 6 continents</li><li>• Multiple product launches since 2018</li><li>• 150+ patents worldwide</li></ul>	<ul style="list-style-type: none"><li>• Anaphylm™ (epinephrine) sublingual film - First and only non-device based, oral product candidate for anaphylaxis<ul style="list-style-type: none"><li>• Anticipate filing for FDA approval in 2024</li></ul></li><li>• Libervant™ (diazepam) buccal film for the treatment of seizure clusters in patients aged 12 and older with epilepsy - Anticipate launch in 2027<ul style="list-style-type: none"><li>• Libervant NDA for use in patients ages 2-5 was accepted by FDA; PDUFA target action date April 28, 2024</li></ul></li></ul>	<ul style="list-style-type: none"><li>• Adrenaverse™ Epinephrine prodrug platform has the potential for multiple future pipeline iterations and indications</li></ul>




# Our Core Technology is Branded as PharmFilm®

*Where You Need It, When You Need It™*




# Our Adrenaverse™ Pro-Drug Platform

AQST-108




Anaphylm (AQST-109)



Adrenaverse™ platform contains a library of over 20 epinephrine prodrugs that can control absorption and conversion rates across a variety of dosage forms and delivery sites

# Product Portfolio & Licensing Opportunities in 2023 and 2024



## Licensing Opportunities

**Libervant™ (diazepam)  
buccal film**

*United States  
Asia  
South America*

**Anaphylm™ (epinephrine)  
sublingual film**

*Ex-U.S. Rights*

## Regional Licensing Agreements

**Hypera – Brazil**

**Zambon - EU**

**Haisco - China**

**Mitsubishi Tanabe – U.S.**

**Ondif®**  
ondansetrona

**emylif®**  
Riluzole  
Orodispersible Film

(riluzole) oral film  
(development stage)

**Exservan™**  
(riluzole) oral film

## Global Licensing Agreements

**Assertio Therapeutics**

**Sympazan®**  
(clobazam) oral film  
5 mg • 10 mg • 20 mg

**Indivior**

**Suboxone® Sublingual Film**  
(buprenorphine and naloxone) ©  
2 mg/0.5 mg • 4 mg/1 mg • 8 mg/2 mg • 12 mg/3 mg

**Pharmanovia**

**Libervant™**  
(diazepam) buccal film

## IP Licenses (Royalty-Only)

**Zevra**

**azstarlys®**  
serdexmethylphenidate  
and dexmethylphenidate  
26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules



# Strong Leadership Team

## Strong Operations & Partnering Team



**Daniel Barber**  
President, CEO and  
Director



**Lori J. Braender**  
SVP, General Counsel



**Ken Marshall**  
Chief Commercial Officer




**Peter Boyd**  
SVP, IT, HR, &  
Communications



**Ernie Toth**  
Chief Financial Officer

## Experienced Science/IP/Development Team



**Mark Schobel**  
Chief Innovation &  
Technology Officer



**Cassie Jung**  
SVP, Operations



**Carl Kraus**  
Chief Medical Officer



**Steve Wargacki**  
SVP, R&D

## We Are Now Focused on the Next Chapter

- Commence pivotal study for Anaphylm™ in Q4 2023
- Continue to strengthen the balance sheet
- Continue to pursue out-licensing opportunities for Libervant™ and Anaphylm™
- Continue to grow our license and supply business

# **Anaphylm™ (epinephrine) Sublingual Film**

Advancing medicines.  
Solving problems.  
Improving lives.

# Anaphylaxis: A Serious Systemic Hypersensitivity Reaction That is Usually Rapid in Onset And May Be Fatal<sup>1</sup>

- As many as **32 million people** in the United States are at chronic risk for acute anaphylactic episodes<sup>2</sup>

---

- Direct costs of anaphylaxis have been estimated at **\$1.2 billion** per year<sup>3</sup>

---

- **52% of patients** in a nationwide patient survey who had previously experienced anaphylaxis had never received an epinephrine auto-injector prescription<sup>3</sup>

---

- **60% of respondents** in same patient survey did not have an epinephrine auto-injector currently available<sup>3</sup>

1. Turner PJ, et al. *World Allergy Org J.* 2019;12100066. 2. FARE, 2022; <https://www.foodallergy.org/resources/facts-and-statistics>. 3. Fromer L. *The American Journal of Medicine* (2016);129, 1244-1250.

# Treatment of Anaphylaxis – Epinephrine

- Epinephrine is the first line of treatment for anaphylaxis<sup>1</sup>
  - *Epinephrine is the only medication proven to stop a life-threatening allergic reaction*
- **Epinephrine dosage (current medication delivery systems):**<sup>2</sup>
  - *0.3-0.5mg intramuscularly (IM) or subcutaneously*
  - *Children's dosage is weight based:*
    1. 0.10mg (for children 16.5 to 33 pounds) — AUVI-Q® brand only
    2. 0.15mg (for children under 66 pounds)
    3. 0.3mg (for children and adults over 66 pounds)
- A second dose of epinephrine can be given as needed<sup>2</sup>




1. [Epinephrine in the Management of Anaphylaxis](#). Brown JC, Simons E, Rudders SA. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1186-1195. doi: 10.1016/j.jaip.2019.12.015 PMID: 32276687. 2. EpiPen® Package Insert.



# Epinephrine Market

The 2022 epinephrine market surpassed 4 million TRx in 2022 and rebounded to historical highs following a downturn due to generics and the Covid-19 pandemic. TRx counts in 2023 have exceeded prior year for 9 consecutive months.<sup>1</sup>



1. Symphony Health September 2023, All Market Data is limited to US & Territories

# Generic Market With High Levels of Dissatisfaction and Unmet Need

## Current Standard of Care = Large, Needle Based Injectors<sup>1</sup>




- Oversized devices
  - *Hard to carry*
  - *Medical guidelines recommend always having 2 doses on hand*
- Needle based
  - *High prevalence of needle phobia (especially in children)*
- Not always intuitive to use
  - *Even trained health care providers have been shown to incorrectly inject*

## Numerous Studies and Patient Surveys Articulate Significant Dissatisfaction with Current Offerings

- Right place, right time<sup>2</sup>
  - *<50% of patients carry their EpiPen® – often due to hassle factor*
- Refusal of treatment<sup>3,4,5</sup>
  - *25-50% of patients refuse treatment with EpiPen® – often due to needle reluctance*
- Time to treat post exposure<sup>1</sup>
  - *60% of patients/caregivers delay treatment – often due to needle reluctance*
- Failed administration in the field<sup>6</sup>
  - *23-35% of patients and caregivers fail to dose correctly*

1. KOL feedback; Aquestive Market Research. 2. Fromer L. The American Journal of Medicine (2016);129, 1244-1250. 3. Warren et al. Ann Allergy Asthma Immunol (2018). 4. Brooks et al. Ann Allergy Asthma Immunol (2017). 5. Asthma and Allergy Foundation of America Patient Survey Report (2019). 6. El Turki et al. EmergMed J (2017).

# Recent FDA Public Document Highlighted the Barriers to Epinephrine Use<sup>1</sup>



1. [https://www.fda.gov/media/168054/download/Slide\\_14\\_](https://www.fda.gov/media/168054/download/Slide_14_)

# Anaphylm™ (epinephrine) Sublingual Film

*First and only non-device based, orally delivered epinephrine product candidate*



Portability

+












Non-device  
administration

+



Fast absorption into  
the bloodstream

# Competitive Product Summary<sup>1</sup>

	ORAL	AUTO INJECTOR				INTRA NASAL		
Company	 <sup>2</sup>	 <sup>3</sup> 				 <sup>2</sup>	 <sup>2, 4</sup>	 <sup>2</sup>
Brand	Anaphylm	EpiPen/Generic	Adrenaclick®	Auvi-Q®	Symjepi®	neffy®	Utuly™	N/A
Administration	Sublingual	Auto-Injector	Auto-Injector	Auto-Injector	Syringe Device	Nasal Spray	Nasal Spray	Nasal Spray
Dosing (Adult/Jr)	TBD	0.3 / 0.15 mg	0.3 / 0.15 mg	0.3 / 0.15 / 0.10 mg	0.3 / 0.15 mg	2 mg	6.6 mg	Not Reported
Market Position	1st & Only Oral	90%+ Share	Negligible	<10%	Negligible	1 Dose per Device	2 Doses per Device	Potentially 3 <sup>rd</sup> Nasal to Market
Regulatory Status (FDA)	Expected NDA Filing 2024	Approved/Marketed				CRL Received – Pending Filing after Study	Expected Filing 1H '23	Expected NDA Filing 2023

1. The data presented on this slide are based on cross-study comparisons and are not based on any head-to-head trials as a result, comparability may be limited/inaccurate. Cross-study comparisons are inherently limited and may suggest misleading similarities or difference. 2. Pending FDA Review. 3. VIATRIS: Formerly Mylan. 4. US WorldMeds markets for Adamis.



# Scientific Advisory Board




**David Bernstein, MD**

*University of Cincinnati*



**Carlos Camargo, MD**

*Harvard Medical School*



**David M. Fleischer, MD**

*Children's Hospital Colorado*



**David Golden, MD**

*Sinai Hospital, Baltimore*



**Matthew Greenhawt, MD**

*Children's Hospital Colorado*



**Ruchi Gupta, MD, MPH**

*Northwestern*



**Jay Lieberman, MD**

*University of Tennessee*




**John Oppenheimer, MD**

*University of Medicine and  
Dentistry of NJ - Rutgers*



# Anaphylm had Similar Exposure to Auto-injectors During the First 10 Minutes Following Dosing<sup>1</sup>

Comparison of epinephrine plasma concentrations over time of Anaphylm 12mg to various approved auto-injectors 0.3mg




Comparison of epinephrine exposure at 10 minutes of Anaphylm 12mg to various approved auto-injectors 0.3mg

Parameter	0.3mg Manual (N=27)	Auvi-Q (N=29)	Anaphylm (N=12)	EpiPen (generic) (N=29)	EpiPen (N=27)
$AUC_{0-10min}$ (hr*pg/mL)	5.3	26.7	28.3	37.7	43.7

1. Cross-study comparison from AQ109102 and AQ109106.

# Repeat Dose – 25 Minutes<sup>1</sup>

Comparison of Anaphylm 12mg repeat dose data (25 minutes)  
to 0.3mg manual injection repeat dose data (10 minutes)




Description	0.3mg Manual Injection Repeat Dose (10 min)	Anaphylm Repeat Dose (25 min)
# Subjects	23	27
C <sub>max</sub> (pg/mL)	755	882
AUC <sub>0-t</sub> (hr*pg/mL)	1300	776
AUC <sub>0-45</sub> (hr*pg/mL)	181	207
Tmax (minutes)	50	33
Tmax Range (minutes)	30 - 70	10 - 70

- Geometric Means presented for C<sub>max</sub>, AUC<sub>0-t</sub>, AUC<sub>0-45</sub>. Median T<sub>max</sub>.
- Data presented from cross-study analysis of AQ109201 (0.3mg manual injection repeat dose at 10 min) and AQ109102 (Anaphylm repeat dose at 25 minutes - top-line results).

1. Cross-study comparison from AQ109201 (EpiPhast II) and AQ109102.



# Anaphylm 12mg and 14mg Exceeds Lower Bracket at All Expected Pivotal Targets<sup>1</sup>




Partial AUC (%CV)	Manual Injection	Anaphylm 12mg	Anaphylm 14mg
AUC0-45min	94.4 (75.6%)	127.6 (124.2%)	222.2 (105.3%)
AUC0-50min	117.2 (72.3%)	138.1 (122.4%)	232.1 (104.6%)
AUC0-60min	160.4 (66.2%)	156.5 (119.4%)	251.7 (103.0%)

1. Bracketing end points subject to alignment with FDA. Cross-study comparison from AQ109102 and AQ109103.

# Key PK Parameters Compare Favorably to Existing Treatments<sup>1</sup>

Anaphylm 12mg and 14mg provide a consistently fast T<sub>max</sub> with median and mean C<sub>max</sub> levels bracketed by the current FDA approved products.



*Bars above show highest and lowest 75% quartile ranges of approved products.*

1. Cross-study comparison of AQ109102 and AQ109103.







# Both 12mg and 14mg Anaphylm Resulted in Clinically Favorable Pharmacodynamic (PD) Effects<sup>1</sup>

Anaphylm demonstrates a rapid increase in systolic blood pressure (SBP), pulse and diastolic blood pressure (DBP) within 2 minutes. Minimal impact to PD from increased exposure provided by Anaphylm 14mg.

Mean Baseline Adjusted Changes in Systolic Blood Pressure Following Administration



Mean Baseline Adjusted Changes in Pulse Following Administration



1. Cross-study comparison of AQ109102 and AQ109103.

# Anaphylm Safety and Tolerability

- In the clinical program to date, treatment emergent adverse events (TEAEs) were assessed by both incidence and severity
  - Vast majority of reported TEAEs were mild or moderate in severity
  - Majority of TEAEs were within the standard of care (SOC) of general disorders and administrative site conditions
  - No serious adverse events (SAEs) reported and most TEAEs resolved without additional intervention
- Cardiovascular adverse event (AE) profile of Anaphylm appears similar to the AE profile of the approved comparators
  - No severe cardiac events have been observed following Anaphylm dosing, and all TEAEs have required no or minimal intervention
  - BP elevations have generally been minimal to moderate in degree; no episodes of malignant hypertension (SBP>180mmHg) were observed
  - Heart rate elevations have generally been minimal to moderate in degree; transient palpitations and tachycardia have frequently been reported, but ventricular tachyarrhythmias were not observed

# Anaphylm 2023-2024 Critical Path


	2023												2024											
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4		
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec
Pilot Studies																								
Pivotal Study																								
Pediatric Study																								
Pre-NDA Meeting																								
NDA Submission																								

# **Libervant™ (diazepam)**

## **Buccal Film**

Advancing medicines.  
Solving problems.  
Improving lives.

# The Unmet Need in Refractory Seizures...




1. Laxer, Ketel, The consequences of Refractory Epilepsy and its treatment; Epilepsy & Behavior, Vol 37, Aug 2014, Pgs 59 –70; <https://doi.org/10.1016/j.yebeh.2014.05.031>. 2. Triangle Insights Group (2017). Synthesis of Epilepsy (ARS) Primary Research. Internal Aquestive report: unpublished. 3. [Epilepsy Data and Statistics | CDC](#) - 1.2% of the US population had active epilepsy (95% CI\* = 1.1-1.4). This is about 3.4 million people with epilepsy nationwide: **3 million adults** and **470,000 children**. 4. [Breakthrough Seizures: Causes, Treatment, and Prevention \(healthline.com\)](#) - About 1 in 3 people with epilepsy experience breakthrough seizures. 5. 2022 Symphony Data shows 420,000 labeled rescue rxs, if a patient fills 2.5 times a year that's 168,000 patients. 6. Seizure visits to ED: [ht t p s:/ /www.ncbi.nlm.nih.gov/pmc/articles/PMC2657249/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657249/).



# Current Treatments are Either Rectal or Intra Nasal Options

**Diastat<sup>®</sup>AcuDial<sup>™</sup>**  
(diazepam rectal gel) 5 mg/mL 

Confirm the dose and green “READY” band are visible.





 **VALTOCO<sup>®</sup>**  
(diazepam nasal spray) 



# Seizure Rescue Annual Volume<sup>1</sup>


*The seizure rescue market has grown significantly with the launches of improved drug delivery options.*



1. Symphony Health September 2023, All Market Data is limited to US & Territories

# Seizure Rescue Market Growth<sup>1</sup>

*The seizure rescue market continues to grow due to new products being promoted.*





1. Symphony Health September 2023, All Market Data is limited to US & Territories



# Seizure Rescue Market by Age<sup>1</sup>

The seizure rescue market has ~60% of the population less than 18 years of age and experiences a significant back to school effect.



1. Symphony Health September 2023, All Market Data is limited to US & Territories

# Strong Patient Preference – What Patients Want<sup>1</sup>

% Indicating	1: Not at all Important	2	3: Somewhat Important	4	5: Highly Important	Top 2 Box
Ability to have the repetitive seizure medicine with me at all times	3%	7%	20%	26%	45%	<b>71%</b>
Ability to take the medicine as quickly as I possibly can when I need to	3%	4%	14%	28%	51%	<b>79%</b>
Ability to take the medicine in a way that is simple for me	2%	2%	13%	23%	60%	<b>83%</b>
Ability to take the medicine no matter where I am and what I am doing	3%	2%	14%	23%	58%	<b>81%</b>
Ability for me to take the medicine myself, versus someone else having to give it to me	5%	3%	22%	28%	43%	<b>71%</b>


1. Aquestive Therapeutics sponsored preference study (N=101 Patients), data on file.

# Strong Patient Preference – Willingness to Request<sup>1</sup>

% Choosing	Strongly Prefer Nasal	Prefer Nasal	No Preference	Prefer Film	Strongly Prefer Film	Film Preference
If both medicines worked just as well at stopping my repetitive seizures, I would prefer my doctor prescribe me:	6%	7%	16%	21%	50%	<b>71%</b>
Likelihood of me asking my doctor if I could switch from the current medicine I have for repetitive seizures to one of the new products:	7%	8%	20%	27%	39%	<b>66%</b>

1. Aquestive Therapeutics sponsored preference study (N=101 Patients), data on file.

# Libervant™ (diazepam) Buccal Film Path to Launch



1. Estimate is based on an orphan drug market exclusivity block until January of 2027 by an FDA approved nasal spray product.



# Existing Collaborations

Advancing medicines.  
Solving problems.  
Improving lives.




# Product Licenses Across the Globe

We currently have eight active worldwide licensing and manufacturing contracts; five more than just two years ago.



# Existing Product Portfolio Has Generated Over \$500M In Revenue





1. Estimate is based on an orphan drug market exclusivity block until January of 2027 by an FDA approved nasal spray product.

# Global Diversification of Suboxone














Suboxone ROW business is expected to grow to 47% of the Suboxone Revenue by 2029<sup>1</sup> reducing the reliance on the Suboxone US market. Suboxone Film is currently distributed in Denmark, Finland, Germany, Italy, Norway, U.K., Sweden, Australia, Canada, Israel, and Malaysia.

**SUBOXONE Film** – Approved in 36 countries ex-U.S. Filings under review in Kuwait, Kingdom of Saudi Arabia and Colombia.

- ✓ Indivior has presence in 39 countries
- ✓ Suboxone Film is approved in 36 countries

-  Available
-  Approved

## Suboxone ROW Market<sup>2</sup>


N. America	Canada	
Europe & Middle East	EU	
	France	
	Italy	
	Germany	
	Denmark, Norway	
	Sweden	
	Finland	
	Switzerland	
	UK	
	Israel	
Australasia	Australia	
	New Zealand	

1. Aquestive Therapeutics data on file. 2. Data from Indivior Jeffries Healthcare Conference Presentation June 7, 2023.


# Suboxone U.S. Market Has Been Stable for Several Years

- Suboxone U.S. market TRx is growing despite lack of promotion and alternative product forms
- Suboxone U.S. market share is on consistent trajectory
- Suboxone U.S. has experienced price stability for several years


Suboxone U.S. Market<sup>2</sup>



Suboxone U.S. Market Share<sup>2</sup>



Suboxone U.S. PAC Pricing<sup>1</sup>



1. Elsevier Gold Standard Pricing Database. 2. Symphony Health Data April 2023. All Market Data is limited to U.S. and its territories.

# Updated Guidance


Advancing medicines.  
Solving problems.  
Improving lives.

# Outlook Update – Revised Guidance


## 2023 Outlook as of November 2023

- Total revenues of approximately \$47 to \$50 million
- Non-GAAP adjusted EBITDA loss less of approximately \$14 to \$17 million

Revenue Guidance Revisions in 2023



Non-GAAP Adjusted EBITDA Guidance Revisions in 2023





# Thank You

Advancing medicines.  
Solving problems.  
Improving lives.